arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Anebulo Pharmaceuticals, Inc.

ANEB

— Price unavailable

6 Visible periods

17 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Anebulo Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -62.5% ↗

FCF / Share $-0.19 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-8.48M

↓ -3.5% —

FCF / Share Free cash flow per share

$-0.19

↑ +40.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗
EPS Growth YoY (%)	21.9% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	31.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-62.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	89.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-3.5% Weak ↓ Weak Declining Year-over-year change in net income	30.1% Excellent ↑ Excellent Improving Year-over-year change in net income	-71.9% Weak Weak Year-over-year change in net income	77.4% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	40.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	18.9% Good ↑ Good Improving Year-over-year change in free cash flow	-65.8% Weak Weak Year-over-year change in free cash flow	34.9% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗
FCF / Net Income (x)	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.16x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗
Return on Invested Capital (%)	-62.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-172.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-87.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-13.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-75.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-204.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-101.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-43.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-16.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-72.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-585%)	-215.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1534%)	-110.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-838%)	-45.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-402%)	-141.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1042%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗
Interest Coverage (x)	-23.06x Weak Weak Operating income divided by interest expense Optimal: > 5x	-41.54x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	-307.11x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-11.63M	$-3.09M	$-11.25M	—	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-0.25	$-0.32	$-0.47	$-0.29	$-2.83	—
Free Cash Flow per Share (USD)	$-0.19	$-0.31	$-0.39	$-0.23	$-0.36	—
Book Value per Share (USD)	$0.28	$0.15	$0.41	$0.65	$0.92	$-0.01
Tangible Book Value per Share (USD)	$0.28	$0.15	$0.41	$0.65	$0.92	$-0.01
Basic Weighted Avg Shares (shares)	33.82M	25.82M	25.07M	23.34M	13.61M	—

🏦 How resilient is the balance sheet? 1 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗
Total Equity (USD)	$11.66M	$3.81M	$10.60M	$15.07M	$21.41M	$-171.14K

📋 What is driving earnings? 2 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗
Net Income, GAAP (USD)	$-8.48M	$-8.20M	$-11.73M	$-6.83M	$-30.25M	—
Operating Cash Flow (USD)	$-6.35M	$-8.09M	$-9.68M	$-5.44M	$-4.87M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 6 years · 23 quarters

Anebulo Pharmaceuticals, Inc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ANEB with peers